CEP-1347   Click here for help

GtoPdb Ligand ID: 8173

Synonyms: CEP 1347 | CEP1347 | KT-7515 | KT7515 [5]
Compound class: Synthetic organic
Comment: CEP-1347 is a semi-synthetic analogue of the natural alkaloid K-252a [5]. CEP-1347 was originally identified as a pan-mixed lineage kinase (MLK) family inhibitor [8]. In this setting it inhibits downstream c-jun N-terminal kinase (JNK) activation and has neuroprotective activity [1-2,7].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

CEP-1347 is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 145.32
Molecular weight 615.19
XLogP 7.52
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CCSCc1ccc2c(c1)c1c3C(=O)NCc3c3c4c1n2C1CC(C(O1)(n4c1c3cc(cc1)CSCC)C)(O)C(=O)OC
Isomeric SMILES CCSCc1ccc2c(c1)c1c3C(=O)NCc3c3c4c1n2[C@H]1C[C@]([C@](O1)(n4c1c3cc(cc1)CSCC)C)(O)C(=O)OC
InChI InChI=1S/C33H33N3O5S2/c1-5-42-15-17-7-9-22-19(11-17)26-27-21(14-34-30(27)37)25-20-12-18(16-43-6-2)8-10-23(20)36-29(25)28(26)35(22)24-13-33(39,31(38)40-4)32(36,3)41-24/h7-12,24,39H,5-6,13-16H2,1-4H3,(H,34,37)/t24-,32+,33+/m1/s1
InChI Key SCMLRESZJCKCTC-KMYQRJGFSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
CEP-1347 was evaluated for Parkinson's disease in humans but failed to demonstrate clinical benefit [6] (see Phase 2/3 clinical study NCT00040404).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
CEP-1347 blocks the activation of -Jun n-terminal kinases (JNKs) by inhibiting upstream mixed lineage kinases (MLKs) [5]. Inhibition of the JNK pathway is proposed to provide neuroprotective effects which may delay the progression of motor dysfunction in neurodegenerative conditions such as Parkinson's disease [4,8].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00040404 Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease Phase 2/Phase 3 Interventional Teva Pharmaceutical Industries